{"filing":{"accession_number":"0001493152-26-031204","cik":"0001828673","ticker":"HCWB","company_name":"HCW Biologics Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/form8-k.htm"},"events":[{"id":14873,"run_id":13257,"accession_number":"0001493152-26-031204","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that HCW Biologics regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)) following a prior non-compliance notice, but remains subject to a mandatory Panel Monitor through June 17, 2027. Critically, the Panel's decision imposes a conditional delisting threat: if the Company falls out of compliance with the Bid Price Rule again during the monitoring period, it will receive an immediate Delist Determination Letter without opportunity for a cure period or compliance plan. This is a material delisting risk disclosure under Item 3.01, as the Company's continued listing is now contingent on maintaining compliance under heightened scrutiny.","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":12445,"accession_number":"0001493152-26-031204","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that HCW Biologics regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)) following a prior non-compliance notice, but remains subject to a mandatory Panel Monitor through June 17, 2027. Critically, the Panel's decision imposes a conditional delisting threat: if the Company falls out of compliance with the Bid Price Rule again during the monitoring period, it will receive an immediate Delist Determination Letter without opportunity for a cure period or compliance plan. This is a material delisting risk disclosure under Item 3.01, as the Company's continued listing is now contingent on maintaining compliance under heightened scrutiny.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:31:52.684842+00:00","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-06-30"}]}